Skip to main content
. Author manuscript; available in PMC: 2011 Apr 28.
Published in final edited form as: N Engl J Med. 2010 Oct 28;363(18):1727–1733. doi: 10.1056/NEJMoa1007056

Figure 2. CT Scans Showing the Response to Crizotinib in Patient 1.

Figure 2

The baseline abdominal CT scan shows a hepatic mass measuring 4.8 by 3.3 cm (top) and one of several mesenteric masses measuring 3.8 by 3.3 cm (bottom) (Panel A, arrows). After 13 weeks of treatment with crizotinib, the hepatic and mesenteric masses measured 2.3 by 0.8 cm and 1.3 by 1.2 cm, respectively (Panel B, arrows). In October 2008, these masses measured 3.6 by 2.2 cm and 0.5 by 0.5 cm, respectively (not shown), indicating that the hepatic mass had regrown, despite a continued response, according to the Response Evaluation Criteria in Solid Tumors.